A: A single dose of MY008211A tablets was administered in the fasting state (fasting for at least 10 h with water as needed).~B: A single dose of MY008211A tablets was administered after a standard high-fat, high-calorie fed.
This was a single-center, single-dose, open-label clinical study. 12 subjects were randomly assigned in a 1:1 ratio to one of the following dosing sequences (sequence 1: AB; Sequence 2: BA). Each dosing sequence consisted of two cycles, one dose per cycle, with a 5-day washout period between doses.